Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET

Company Participants

Luis Sanay - Vice President, Investor Relations
John Jacobs - President and Chief Executive Officer
John Trizzino - President and Chief Operating Officer
Robert Walker - Senior Vice President and Chief Medical Officer
Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer

Conference Call Participants

Roger Song - Jefferies
Mayank Mamtani - B. Riley Securities
Eric Joseph - JPMorgan
Vernon Bernardino - H.C. Wainwright

Operator

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the call over to Luis Sanay, Vice President, Investor Relations. Please go ahead.

Luis Sanay

Good morning and thank you all for joining us today to discuss our third quarter 2024 operational highlights and financial results. A press release announcing our results is currently available on our website at novavax.com and an audio archive of this conference call will be available on our website later today.

Please turn to Slide 2. Before we begin with prepared remarks, I need to remind you that, this presentation includes forward-looking statements, including, but not limited to, statements related to Novavax's corporate strategy and operating plans, its value drivers and near-term priorities, its partnerships and expectations with respect to potential royalties, milestones and cost reimbursements, its expectations regarding manufacturing capacity, timing, production and delivery for its COVID-19 vaccine, the development of Novavax's clinical and preclinical product candidates, full year 2024 financial guidance and Novavax's future financial or business performance.

Each forward-looking statement contained in this presentation is subject to certain risks and uncertainties that could cause actual results to differ materially from those projected in such statements. Additional information regarding these factors appears under the heading Cautionary Note regarding forward-looking statements in the presentation we issued this morning and under the heading Risk Factors in our most recent Form 10-K and subsequent Form 10-Qs, filed with the Securities and Exchange Commission available at sec.gov and on our website at novavax.com. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.

Please turn to Slide 3. This presentation also includes references to a non-GAAP financial measure, which is forward-looking information for combined R&D and SG&A expense as adjusted for expense reimbursement from Sanofi under the Sanofi agreement.